Key Points
- CEO Christopher Hall sold 7,459 Personalis shares at an average price of $16.22, generating approximately $120,985. The sale covered tax-withholding obligations tied to vested equity awards, leaving him with 228,527 shares.
- Personalis reported quarterly revenue of $22.36 million, exceeding estimates of $16.69 million, but its adjusted loss of $0.30 per share missed expectations by $0.04. Analysts forecast a full-year loss of $1.07 per share.
- The stock has risen substantially from its 52-week low of $4.95, opening at $16.36, while analyst sentiment remains mixed: the consensus rating is Hold with an average price target of $14.54.
Personalis, Inc. (NASDAQ:PSNL - Get Free Report) SVP Stephen Moore sold 2,068 shares of the business's stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $16.22, for a total transaction of $33,542.96. Following the sale, the senior vice president owned 90,257 shares of the company's stock, valued at $1,463,968.54. This represents a 2.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Personalis Trading Up 0.7%
Shares of Personalis stock opened at $16.36 on Wednesday. The company has a fifty day simple moving average of $15.09 and a 200-day simple moving average of $10.94. The stock has a market cap of $1.71 billion, a price-to-earnings ratio of -15.01 and a beta of 2.31. Personalis, Inc. has a 12-month low of $4.95 and a 12-month high of $18.89.
Personalis (NASDAQ:PSNL - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.04). Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. The company had revenue of $22.36 million during the quarter, compared to analysts' expectations of $16.69 million. On average, analysts forecast that Personalis, Inc. will post -1.07 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Personalis
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Tidal Investments LLC acquired a new position in Personalis in the 2nd quarter valued at about $1,146,000. WINTON GROUP Ltd acquired a new stake in Personalis during the 2nd quarter worth approximately $496,000. Engineers Gate Manager LP acquired a new stake in Personalis during the 2nd quarter worth approximately $1,552,000. Squarepoint Ops LLC purchased a new position in shares of Personalis in the 2nd quarter valued at approximately $319,000. Finally, Arizona State Retirement System grew its stake in shares of Personalis by 28.2% in the 2nd quarter. Arizona State Retirement System now owns 18,766 shares of the company's stock valued at $251,000 after purchasing an additional 4,131 shares during the last quarter. Hedge funds and other institutional investors own 61.91% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research analysts recently issued reports on PSNL shares. Wall Street Zen downgraded Personalis from a "hold" rating to a "sell" rating in a research note on Saturday, June 13th. Craig Hallum cut Personalis from a "buy" rating to a "hold" rating and set a $16.25 price objective for the company. in a research note on Monday, August 24th. Zacks Research raised Personalis from a "strong sell" rating to a "hold" rating in a report on Monday, September 7th. TD Cowen restated a "buy" rating on shares of Personalis in a research report on Wednesday, July 15th. Finally, Morgan Stanley lifted their target price on shares of Personalis from $9.00 to $13.00 and gave the company an "equal weight" rating in a report on Thursday, July 9th. Four equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $14.54.
View Our Latest Stock Analysis on PSNL
Personalis Company Profile
(
Get Free Report)
Personalis, Inc is a genomics company focused on precision oncology and advanced molecular testing. The company develops and commercializes genomic products designed to help identify, monitor and characterize cancer, supporting more informed treatment decisions and the development of targeted therapies.
Its offerings include tissue- and blood-based tumor profiling, liquid biopsy testing and immune profiling. Personalis' technologies are designed to detect and track tumor-derived signals, evaluate genomic alterations and provide insights into the interaction between cancer and the immune system.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
